- A lower court ruling voiding Amarin’s patents was upheld by a court of appeals and the US Supreme Court declined to take up the matter.
- With one approved drug and a value chain built on differentiation that is facing US market erosion from generics, Amarin would not seem an enticing target for acquisition.
- Seemingly protected by patents in Europe, the European Medicines Agency approved Vazkepa (Vascepa) and Amarin will commercialize in Europe by going-it-alone. It also has approval to commercialize in Canada.
- Amarin, like many, views China as an enticing growth opportunity and expects a decision on commercialization by the end of 2021, supporting their premise on global growth.
- The salient question shareholders understandably struggle with is whether Amarin is a candidate for acquisition. The answer is not simple.
For further details see:
Amarin: Let's Revisit The M&A Discussion